Structure activity relationship studies on C2 side chain substituted 1,1-bis(4-methoxyphenyl)-2-phenylalkenes and 1,1,2-tris(4-methoxyphenyl)alkenes

Journal of Steroid Biochemistry and Molecular Biology

Volumn 87, Issue 1, 2003, Pages 75-83

  Gust, Ronald ^a   Lubczyk, Veronika ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Cytotoxicity; MCF 7 and MDA MB 231 breast cancer cells; Triarylalkenes

Indexed keywords

1,1 BIS(4 METHOXYPHENYL) 2 PHENYLPENT 1 ENE; 4 HYDROXYTAMOXIFEN; 4,5,5 TRIS(4 METHOXYPHENYL)PENT 4 ENYL; 5,5 BIS(4 METHOXYPHENYL) 4 PHENYLPENT 4 ENYLAMINE; 5,6,6 TRIS(4 HYDROXYPHENYL)HEX 5 ENOIC ACID; 5,6,6 TRIS(4 METHOXYPHENYL)HEX 5 ENENITRILE; 6,6 BIS(4 METHOXYPHENYL) 5 PHENYLHEX 5 ENENITRILE; 6,6 BIS(4 METHOXYPHENYL) 5 PHENYLHEX 5 ENOIC ACID; ALKENE DERIVATIVE; ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR; TAMOXIFEN; UNCLASSIFIED DRUG;

ARTICLE; CELL STRAIN MCF 7; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DRUG POTENCY; DRUG SYNTHESIS; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PLASMID; STRUCTURE ACTIVITY RELATION;

MINK CELL FOCUS-FORMING VIRUS; STAPHYLOCOCCUS PHAGE 3A;

EID: 0242662631     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(03)00385-6     Document Type: Article

References (30)

1. Jordan V.C. A current view of tamoxifen for the treatment and prevention of breast cancer. Br. J. Pharmacol. 110:1993;507-517.
2. Fisher B., Costantino J.P., Wickerham D.L., Redmond C.K., Kavanah M., Cronin W.M., Vogel V., Robidoux A., Dimitrov N., Atkins J., Daly M., Wieland S., Tan-Chiu E., Ford L., Wolmark N. National surgical adjuvant breast and bowel project P-1 study. J. Natl. Can. Inst. 90:1998;1371-1388.
3. Fisher B., Costantino J.P., Redmond C.K., Fisher E.R., Wickerham D.L., Cronin W.M. Endometrial cancer in tamoxifen treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J. Natl. Can. Inst. 86:1994;527-537.
4. Rutqvist L.E., Johansson H., Signomklao T., Johansson U., Fornander T., Wilking N. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J. Natl. Can. Inst. 87:1995;645-651.
5. Jordan V.C. Tamoxifen and tumorigenicity: a predictable concern. J. Natl. Can. Inst. 87:1995;623-626.
6. Palkowitz A.D., Glasebrook A.L., Thrasher K.J., Hauser K.L., Short L.L., Phillips D.L., Muehl B.S., Sato M., Shetler P.K., Cullinan G.J., Pell T.R., Bryant H.U. Discovery and synthesis of [6-hydroxy-3-[4-[2-(1-piperidinyl)ethoxy] phenoxy]-2-(4-hydroxyphenyl)]benzo[b]thiophene: a novel, highly potent, selective estrogen receptor modulator. J. Med. Chem. 40:1997;1407-1416.
7. Grese T.A., Cho S., Finley D.R., Godfrey A.G., Jones C.D., Lugar C.W. III, Martin M.J., Matsumoto K., Pennington L.D., Winter M.A., Adrian M.D., Cole H.W., Magee D.E., Phillips D.L., Rowley E.R., Short L.L., Glasebrook A.L., Bryant H.U. Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene. J. Med. Chem. 40:1997;146-167.
8. Hafner F., Holler E., von Angerer E. Effect of growth factors on estrogen receptor mediated gene expression. J. Steroid Biochem. Mol. Biol. 58:1996;385-393.
9. Lubczyk V., Bachmann H., Gust R. Investigations on estrogen receptor binding. The estrogenic, antiestrogenic and cytotoxic properties of C2-alkyl-substituted 1,1-bis(4-hydroxyphenyl)-2-phenylalkenes. J. Med. Chem. 45:2002;5358-5364.
10. Lubczyk V., Bachmann H., Gust R. Antiestrogenically active 1,1,2-tris(4-hydroxyphenyl)alkenes without basic side chain: synthesis and biological activity. J. Med. Chem. 46:2003;1484-1491.
11. Gust R., Lubczyk V. Investigations on the influence of terminal groups at the C2-propyl side chain of 1,1-bis(4-hydroxyphenyl)-2-phenylpent-1-ene and 1,1,2-tris(4-hydroxyphenyl)pent-1-ene on the estrogen receptor binding and the estrogenic and anti-estrogenic properties. J. Steroid Biochem. Mol. Biol. 86:2003;57-70.
12. Hay R.J. The seed stock concept and quality control for cell lines. Anal. Biochem. 171:1988;225-237.
13. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
14. Mitlak B.H., Cohen F.J. Selective estrogen receptor modulators. A look ahead. Drugs. 57:1999;653-663.
15. Han X., Liehr J.G. Induction of covalent DNA adducts in rodents by Tamoxifen. Cancer Res. 52:1992;1360-1363.
16. Mani C., Kupfer D. Cytochrome P450 mediated action and irreversible binding of the antiestrogen tamoxifen to proteins in rat and human liver: possible involvement of the flavin-containing monooxygenases in tamoxifen action. Cancer Res. 51:1991;6052-6058.
17. 14C ]tamoxifen to liver microsome and the forms of cytochrome P450 involved Biochem. Pharmacol. 49:1995;1035-1042.
18. Phillips D.H., Carmichael P.L., Hewer A., Cole K.J., Poon G.K. Alpha-hydroxytamoxifen, a metabolite of tamoxifen with exceptionally high DNA-binding activity in rat hepatocytes. Cancer Res. 54:1994;5518-5522.
19. Shibutani S., Dasaradhi L., Terashima I., Banoglu E., Duffel M.W. Alpha-hydroxytamoxifen is a substrate of hydroxysteroid (alcohol) sulfotransferase, resulting in tamoxifen DNA adducts. Cancer Res. 58:1998;647-653.
20. Sanchez C., Shibutani S., Dasaradhi L., Bolton J.L., Fan P.W., McClelland R.A. Lifetime and reactivity of an ultimate tamoxifen carcinogen: the tamoxifen carbocation. J. Am. Chem. Soc. 120:1998;13513-13514.
21. Fan P.W., Zhang F., Bolton J.L. 4-Hydroxylated metabolites of the antiestrogens tamoxifen and toremifene are metabolized to unusually stable quinone methides. Chem. Res. Toxicol. 13:2000;45-52.
22. Kuramochi H. Conformational studies and electronic structures of tamoxifen and toremifen and their allylic carbocations proposed as reactive intermediates leading to DNA adduct formation. J. Med. Chem. 39:1996;2877-2886.
23. Chouvet C., Saez S. High affinity cytosol binding site(s) for antiestrogens in two human breast cancer cell lines and in biopsy specimens devoid of estrogen receptors. J. Steroid Biochem. Mol. Biol. 21:1984;755-761.
24. Leonessa F., Jacobson M., Boyle B., Lippman J., McGarvey M., Clarke R. Effect of tamoxifen on the multidrug-resistant phenotype in human breast cancer cells: isobologram, drug accumulation, and M(r) 170,000 glycoprotein (gp170) binding studies. Cancer Res. 54:1994;441-447.
25. Lopes M.C., Vale M.G., Carvalho A.P. Ca2(+)-dependent binding of tamoxifen to calmodulin isolated from bovine brain. Cancer Res. 50:1990;2753-2758.
26. Bignon E., Pons M., Dore J.C., Gilbert J., Ojasoo T., Miquel J.F., Raynaud J.P., Crastes de Paulet A. Influence of di- and tri-phenylethylene estrogen/antiestrogen structure on the mechanisms of protein kinase C inhibition and activation as revealed by a multivariate analysis. Biochem. Pharm. 42:1991;1373-1383.
27. Fiucci G., Czarny M., Lavie Y., Zhao D., Berse B., Blusztajn J.K., Liscovitch M. Changes in phospholipase D isoform activity and expression in multidrug-resistant human cancer cells. Int. J. Cancer. 85:2000;882-888.
28. Zhao Y., Ehara H., Akao Y., Shamoto M., Nakagawa Y., Banno Y., Deguchi T., Ohishi N., Yagi K., Nozawa Y. Increased activity and intranuclear expression of phospholipase D2 in human renal cancer. Biochem. Biophys. Res. Commun. 278:2000;140-143.
29. Lavie Y., Zhang Z., Cao H., Han T., Jones R.C., Liu Y., Jarman M., Hardcastle I.R., Giuliano A.E., Cabot M.C. Tamoxifen induces selective membrane association of protein kinase C epsilon in MCF-7 human breast cancer cells. Int. J. Cancer. 77:1998;928-932.
30. Jonnalagadda S.S., ter Haar E., Hamel E., Lin C.M., Magarian R.A., Day B.W. Synthesis and biological evaluation of 1,1-dichloro-2,3- diarylcyclopropanes as antitubulin and anti-breast cancer agents. Bioorg. Med. Chem. 5:1997;715-722.